Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells

被引：0
|
作者：
Amjad Ali
Hema Unnikannan
Jasmin Shafarin
Khuloud Bajbouj
Jalal Taneera
Jibran Sualeh Muhammad
Haydar Hasan
Albert Salehi
Samir Awadallah
Mawieh Hamad
机构：
[1] University of Sharjah,Sharjah Institute for Medical Research
[2] University of Sharjah,Department of Basic Medical Sciences, College of Medicine
[3] University of Sharjah,Department of Clinical Nutrition and Dietetics, College of Health Sciences
[4] Lund University,Department of Clinical science, UMAS, Clinical Research Center
[5] University of Gothenburg,Department of Neuroscience and Physiology, Metabolic Research Unit
[6] University of Sharjah,Department of Medical Laboratory Sciences, College of Health Sciences
来源：
Endocrine | 2022年 / 76卷
关键词：
Metformin; PCSK9; HNF-1α; SREBP2; LDL-cholesterol; LDLR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [1] Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells
    Ali, Amjad
    Unnikannan, Hema
    Shafarin, Jasmin
    Bajbouj, Khuloud
    Taneera, Jalal
    Muhammad, Jibran Sualeh
    Hasan, Haydar
    Salehi, Albert
    Awadallah, Samir
    Hamad, Mawieh
    ENDOCRINE, 2022, 76 (03) : 543 - 557
  • [2] Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition
    Wierzbicki, Anthony S.
    Grant, Paul
    CLINICAL MEDICINE, 2016, 16 (04) : 353 - 357
  • [3] Pro protein convertase subtilisin kexin type 9 (PCSK9) inhibitors Pharmacological review and update
    Corral, Pablo
    Suter, Agustina
    Rusconi, Alejandro
    Trigo, Leandro
    INSUFICIENCIA CARDIACA, 2016, 11 (03) : 122 - 129
  • [4] LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
    Sabatel-Perez, F.
    Garcia-Ropero, A.
    Santos-Gallego, G.
    Zafar, M. Urooj
    Badimon, J. J.
    DRUGS OF TODAY, 2019, 55 (05) : 329 - 344
  • [5] Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes
    Kourimate, Sanae
    Chetiveaux, Maud
    Jarnoux, Anne Laure
    Lalanne, Florent
    Costet, Philippe
    ATHEROSCLEROSIS, 2009, 206 (01) : 134 - 140
  • [6] Proprotein Convertase Subtilisin Kexin9 (PCSK9): A Novel Target For Cholesterol Regulation
    Basak, Ajoy
    Palmer-Smith, Heather
    Mishra, Priyambada
    PROTEIN AND PEPTIDE LETTERS, 2012, 19 (06) : 575 - 585
  • [7] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
    O'Connell, Emma M.
    Lohoff, Falk W.
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [8] Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
    Grewal, Thomas
    Buechler, Christa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [9] Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
    Zhu, Yiming M.
    Anderson, Todd J.
    Sikdar, Khokan
    Fung, Marinda
    McQueen, Matthew J.
    Lonn, Eva M.
    Verma, Subodh
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (10) : 2254 - 2259
  • [10] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): Lessons Learned from Patients with Hypercholesterolemia
    Awan, Zuhier
    Baass, Alexis
    Genest, Jacques
    CLINICAL CHEMISTRY, 2014, 60 (11) : 1380 - 1389
12345